RU95121748A - TABLET WITH IMPROVED BIOAVAILABILITY OF A BIOLOGICALLY ACTIVE SUBSTANCE - CLODRONIC ACID - Google Patents

TABLET WITH IMPROVED BIOAVAILABILITY OF A BIOLOGICALLY ACTIVE SUBSTANCE - CLODRONIC ACID

Info

Publication number
RU95121748A
RU95121748A RU95121748/14A RU95121748A RU95121748A RU 95121748 A RU95121748 A RU 95121748A RU 95121748/14 A RU95121748/14 A RU 95121748/14A RU 95121748 A RU95121748 A RU 95121748A RU 95121748 A RU95121748 A RU 95121748A
Authority
RU
Russia
Prior art keywords
biologically active
active substance
tablet
clodronic acid
tablet according
Prior art date
Application number
RU95121748/14A
Other languages
Russian (ru)
Other versions
RU2134103C1 (en
Inventor
Прайс Вальтер
Мюзель Бернд
Нойгебауер Гюнтер
Габель Рольф-Дитер
Original Assignee
Берингер Маннхайм ГмбХ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE9307393U external-priority patent/DE9307393U1/en
Priority claimed from DE19934322057 external-priority patent/DE4322057A1/en
Application filed by Берингер Маннхайм ГмбХ filed Critical Берингер Маннхайм ГмбХ
Priority claimed from PCT/EP1993/001967 external-priority patent/WO1994026310A1/en
Publication of RU95121748A publication Critical patent/RU95121748A/en
Application granted granted Critical
Publication of RU2134103C1 publication Critical patent/RU2134103C1/en

Links

Claims (12)

1. Таблетка с улучшенной биодоступностью биологически активного вещества - клодроновой кислоты или ее физиологически приемлемой соли - с содержанием микрокристаллической целлюлозы в качестве фармацевтического вспомогательного вещества.1. A tablet with improved bioavailability of a biologically active substance - clodronic acid or its physiologically acceptable salt - containing microcrystalline cellulose as a pharmaceutical excipient. 2. Таблетка по п.1 с содержанием микрокристаллической целлюлозы 5 - 15% в расчете на общую массу таблетки. 2. The tablet according to claim 1 with a microcrystalline cellulose content of 5-15%, based on the total weight of the tablet. 3. Таблетка по п.1 или 2 с содержанием биологически активного вещества - клодроновой кислоты - в количестве 200 - 700 мг. 3. The tablet according to claim 1 or 2 with a content of biologically active substance - clodronic acid - in an amount of 200 to 700 mg. 4. Таблетка по пп.1 - 3, содержащая биологически активное вещество в форме динатриевой соли, предпочтительно, в виде тетрагидрата. 4. The tablet according to claims 1 to 3, containing the biologically active substance in the form of disodium salt, preferably in the form of tetrahydrate. 5. Таблетка по пп.1 - 4, содержащая дополнительно наполнитель, в особенности кукурузный крахмал или тальк. 5. A tablet according to claims 1 to 4, further comprising a filler, in particular corn starch or talc. 6. Таблетка по пп.1 - 5, содержащая дополнительно смазку и разрыхлитель. 6. The tablet according to claims 1 to 5, additionally containing lubricant and baking powder. 7. Таблетка по пп.1 - 6, причем смазка представляет собой физиологически приемлемую соль стеариновой кислоты, предпочтительно стеарат магния, и разрыхлитель представляет собой натрийкарбоксиметилкрахмал. 7. The tablet according to claims 1 to 6, wherein the lubricant is a physiologically acceptable salt of stearic acid, preferably magnesium stearate, and the disintegrant is sodium carboxymethyl starch. 8. Таблетка по пп. 1 - 7 с содержанием клодроновой кислоты в качестве биологически активного вещества 420 - 460 мг и с общей массой таблетки 750 - 850 мг, предпочтительно 790 - 810 мг. 8. The tablet according to paragraphs. 1 to 7 with a content of clodronic acid as a biologically active substance 420 to 460 mg and with a total tablet weight of 750 to 850 mg, preferably 790 to 810 mg. 9. Таблетка по пп. 1 - 7 с содержанием клодроновой кислоты в качестве биологически активного вещества 500 - 530 мг и с общей массой таблетки 870 - 970 мг, предпочтительно 900 - 950 мг. 9. The tablet according to paragraphs. 1 to 7 with a content of clodronic acid as a biologically active substance of 500 to 530 mg and with a total tablet weight of 870 to 970 mg, preferably 900 to 950 mg. 10. Таблетка по пп.1 - 7 с содержанием клодроновой кислоты в качестве биологически активного вещества примерно 200 - 270 мг и с общей массой таблетки 350 - 500 мг. 10. The tablet according to claims 1 to 7 with the content of clodronic acid as a biologically active substance of about 200-270 mg and with a total tablet weight of 350-500 mg. 11. Применение биологически активного вещества - клодроновой кислоты или ее физиологически приемлемой соли - и микрокристаллической целлюлозы в качестве фармацевтического вспомогательного вещества для приготовления таблетки с улучшенной биодоступностью биологически активного вещества. 11. The use of a biologically active substance - clodronic acid or its physiologically acceptable salt - and microcrystalline cellulose as a pharmaceutical auxiliary substance for the preparation of tablets with improved bioavailability of the biologically active substance. 12. Применение по п. 11 для приготовления таблетки обычной величины с двухкратной эффективностью. 12. The use according to p. 11 for the preparation of tablets of normal size with double efficiency.
RU95121748A 1993-05-15 1993-07-24 Tablet exhibiting improved bioavailability of biologically active substance and substance enhancing bioavailability RU2134103C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE9307393U DE9307393U1 (en) 1993-05-15 1993-05-15 Tablet with improved bioavailability, containing dichloromethylene diphosphonic acid as an active ingredient
DEG9307393.3U 1993-05-15
DEP4322057.6 1993-07-02
DE19934322057 DE4322057A1 (en) 1993-07-02 1993-07-02 Tablet with improved bioavailability containing dichloromethylenediphosphonic acid as active ingredient
PCT/EP1993/001967 WO1994026310A1 (en) 1993-05-15 1993-07-24 More easily biologically absorbed tablet containing dichloromethylene diphosphonic acid as the active agent

Publications (2)

Publication Number Publication Date
RU95121748A true RU95121748A (en) 1998-03-27
RU2134103C1 RU2134103C1 (en) 1999-08-10

Family

ID=25927331

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95121748A RU2134103C1 (en) 1993-05-15 1993-07-24 Tablet exhibiting improved bioavailability of biologically active substance and substance enhancing bioavailability

Country Status (25)

Country Link
US (1) US5650168A (en)
EP (2) EP0697890A1 (en)
JP (1) JP3699110B2 (en)
KR (1) KR100263284B1 (en)
CN (1) CN1041797C (en)
AT (2) ATE128363T1 (en)
AU (1) AU687744B2 (en)
BR (1) BR9307859A (en)
CA (1) CA2162470C (en)
CZ (1) CZ287984B6 (en)
DE (1) DE59300688D1 (en)
DK (1) DK0625355T5 (en)
ES (1) ES2065313T5 (en)
FI (1) FI111519B (en)
GR (2) GR940300095T1 (en)
HU (1) HU220872B1 (en)
IL (1) IL106743A (en)
NO (1) NO307548B1 (en)
NZ (1) NZ254765A (en)
PL (1) PL173026B1 (en)
RU (1) RU2134103C1 (en)
SK (1) SK281193B6 (en)
TW (1) TW350772B (en)
UA (1) UA39884C2 (en)
WO (1) WO1994026310A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94926C (en) 1993-11-12 1995-11-27 Leiras Oy Method for preparing a clodronate preparation
DE19615812A1 (en) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmaceutical preparation containing diphosphonic acids for oral administration
DE19719680A1 (en) 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Use of diphosphonic acids for the preventive treatment of long-term consequences of bladder enlargement or replacement
FI109088B (en) * 1997-09-19 2002-05-31 Leiras Oy Tablet and process for its preparation
EP0998932A1 (en) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Solid pharmaceutical dosage form containing diphosphonates or their salts and method for its production
SE9901272D0 (en) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
CZ289261B6 (en) * 2000-07-11 2001-12-12 Léčiva, A.S. Tablet that can be produced by direct tabletting, containing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid as active compound and process for producing thereof
US8163306B2 (en) * 2003-09-19 2012-04-24 Sun Pharma Advanced Research Company Oral drug delivery system
US10213387B2 (en) 2003-09-19 2019-02-26 Sun Pharma Advanced Research Company Ltd. Oral drug delivery system
US10226428B2 (en) 2003-09-19 2019-03-12 Sun Pharma Advanced Research Company Ltd. Oral drug delivery system
US7151400B2 (en) * 2004-07-13 2006-12-19 Taiwan Semiconductor Manufacturing Company, Ltd. Boost-biased level shifter
CN100370972C (en) * 2006-01-10 2008-02-27 北京申科联华科技有限公司 Heart boosting pulse restoring tablet and its preparation method
CA2694638A1 (en) * 2007-08-02 2009-02-05 Teijin Pharma Limited Preventive or therapeutic agent for diseases caused by abnormal bone metbolism
WO2009122431A2 (en) * 2008-02-15 2009-10-08 Sun Pharma Advanced Research Company Ltd., Oral controlled release tablet

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2813121A1 (en) * 1977-03-29 1978-10-12 Procter & Gamble Di:chloromethane di:phosphonate compsns. - for stimulating collagen formation and treating of healing wounds and rheumatic and allied disorders
US4634691A (en) * 1980-10-07 1987-01-06 The Procter & Gamble Company Method for inhibiting tumor metastasis
US4517179A (en) * 1983-04-29 1985-05-14 Pennwalt Corporation Rapid dissolving, uniform drug compositions and their preparation
SE457326B (en) * 1986-02-14 1988-12-19 Lejus Medical Ab PROCEDURES FOR PREPARING A QUICK SUBSTANTIAL CANDLES CONTAINING BLA MICROCRISTALLIN CELLULOSA
ATE60711T1 (en) * 1986-12-20 1991-02-15 Boehringer Mannheim Gmbh PHARMACEUTICALS CONTAINING CLODRONATE AND METHOD OF MANUFACTURE THE SAME.
DE3804686A1 (en) * 1988-02-15 1989-08-24 Henkel Kgaa MEDICAMENT WITH A COMBINATION OF CYTOSTATIKA BZW. HORMONTHERAPEUTICS AND PHOSPHONOR DERIVATIVES
FR2629716B1 (en) * 1988-04-07 1991-07-19 Sanofi Sa PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION BASED ON A DIPHOSPHONIC ACID DERIVATIVE
FI83421C (en) † 1989-06-21 1991-07-10 Huhtamaeki Oy FOERFARANDE FOER FRAMSTAELLNING AV FARMAKOLOGISKT ANVAENDBARA METYLENBISFOSFONSYRADERIVAT.
DK0573604T3 (en) * 1991-02-26 1995-05-29 Procter & Gamble Pharma Method of treating osteoporosis
SE501389C2 (en) * 1992-04-24 1995-01-30 Leiras Oy Pharmaceutical preparation and process for its preparation
AU5953894A (en) * 1992-12-23 1994-07-19 Merck & Co., Inc. Bisphosphonate/estrogen therapy for treating and preventing bone loss

Similar Documents

Publication Publication Date Title
RU95121748A (en) TABLET WITH IMPROVED BIOAVAILABILITY OF A BIOLOGICALLY ACTIVE SUBSTANCE - CLODRONIC ACID
US4556678A (en) Sustained release propranolol tablet
RU2294743C2 (en) Valsartan-base solid oral dosing formulations
US20030175341A1 (en) Controlled release formulation
SE8304393L (en) NAPROXEN AND NAPROXEN SODIUM TABLETS OF CONTROLLED RELEASE TYPE
CA2346662A1 (en) Compositions containing diphosphonic acids
AU1531199A (en) Pharmaceutical suspension tablet compositions
RU96116411A (en) QUICKLY DISPERSABLE READY-FORMED DRUG FORM TRAMADOL OR TRAMADOL SALT
HUP0105463A2 (en) Controlled release formulation of divalproex sodium
HU227759B1 (en) Improved pharmaceutical formulations containing ibuprofen and codeine
IL76332A0 (en) Solid medicament formulation containing nitrendipine and its preparation
US4781925A (en) Calcium supplement compressed tablets
FI111519B (en) Process for the preparation of a tablet containing dichloromethylene phosphonic acid as an active ingredient
CA2469019C (en) Pharmaceutical composition comprising a 5ht1 receptor agonist
US4716042A (en) Stabilized coated aspirin tablets
AU776965B2 (en) Composition comprising ascorbic acid and pectin
KR890006235A (en) Pharmaceutical Compositions for Piperidinoalkanols
DE29921300U1 (en) Medicinal product containing paroxetine methanesulfonate
EP0126453B1 (en) Controlled release tablet
CA2373962C (en) Immediate release medicinal compositions for oral use
US4215117A (en) Stable pharmaceutical formulations
ZA200402007B (en) Controlled release formulation of clarithromycin or tinidazol.
MXPA00010368A (en) Stabile compositions comprising levosimendan and alginic acid.
US20060189565A1 (en) Pharmaceutical compositions of ganciclovir
AU2002228264A1 (en) Controlled release formulation of clarithromycin or tinidazol